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Roseguini BT, Hirai DM, Alencar MC, Ramos RP, Silva BM, Wo-
losker N, Neder JA, Nery LE. Sildenafil improves skeletal muscle oxygen-
ation during exercise in men with intermittent claudication. Am J Physiol
Regul Integr Comp Physiol 307: R396–R404, 2014. First published June 18,
2014; doi:10.1152/ajpregu.00183.2014.—Endothelial dysfunction caused
by defective nitric oxide (NO) signaling plays a pivotal role in the
pathogenesis of intermittent claudication (IC). In the present study, we
evaluated the acute effects of sildenafil, a phosphodiesterase type 5
inhibitor that acts by prolonging NO-mediated cGMP signaling in
vascular smooth muscle, on blood pressure (BP), skeletal muscle
oxygenation, and walking tolerance in patients with IC. A random-
ized, double-blind, crossover study was conducted in which 12 men
with stable IC received two consecutive doses of 50 mg of sildenafil
or matching placebo and underwent a symptom-limited exercise test
on the treadmill. Changes in gastrocnemius deoxy-hemoglobin by
near-infrared spectroscopy estimated peripheral muscle O2 delivery-
to-utilization matching. Systolic BP was significantly lower during the
sildenafil trial relative to placebo during supine rest (15 mmHg),
submaximal exercise (14 mmHg), and throughout recovery (18
mmHg) (P  0.05). Diastolic BP was also lower after sildenafil
during upright rest (6 mmHg) and during recovery from exercise
(7 mmHg) (P  0.05). Gastrocnemius deoxygenation was consis-
tently reduced during submaximal exercise (41%) and at peak
exercise (34%) following sildenafil compared with placebo (P 
0.05). However, pain-free walking time (placebo: 335  42 s vs.
sildenafil: 294  35 s) and maximal walking time (placebo: 701  58
s vs. sildenafil: 716  62 s) did not differ between trials. Acute
administration of sildenafil lowers BP and improves skeletal muscle
oxygenation during exercise but does not enhance walking tolerance
in patients with IC. Whether the beneficial effects of sildenafil on
muscle oxygenation can be sustained over time and translated into
positive clinical outcomes deserve further consideration in this patient
population.
intermittent claudication; sildenafil; blood flow; exercise
ATHEROSCLEROTIC PERIPHERAL artery disease (PAD) is an esca-
lating, highly debilitating disease that affects 202 million
people worldwide (15). The most common clinical presenta-
tion of PAD is intermittent claudication (IC), defined as pain in
the legs during ambulatory activity (63). Impaired leg func-
tioning in these individuals leads to reduced mobility and
impaired exercise capacity, which negatively affect quality of
life and contribute to an accelerated decline in functional
capacity (29, 30, 43, 46). Individuals with PAD perform
simple functional tasks at slower rates than individuals
without the disease (31). These patients are also at greater
risk of dying from cardiovascular events (3). Thus, preven-
tion of mobility loss and reduction of cardiovascular risk are
current major goals in the management of PAD (28).
Endothelial dysfunction caused, in part, by deficient nitric
oxide (NO) production and/or increased bioinactivation is a
central feature in the pathophysiology of IC (7, 25). Systemic
biomarkers of NO metabolism and endothelial-dependent di-
lation of the calf resistance vessels are known to be severely
reduced in these patients (1, 7, 25). Among other conse-
quences, impaired NO signaling and reduced vascular respon-
siveness may contribute to the impairment in leg blood flow
responses to exercise in these individuals (58). A recent study
that employed magnetic resonance imaging showed that calf
muscle blood flow is reduced by as much as 40% during peak
plantar flexion exercise in claudicants compared with healthy
controls (41). At the microcirculatory level, numerous reports
have documented that near-infrared spectroscopy (NIRS)-de-
rived measures of muscle deoxygenation increase prematurely
and to a greater extent during treadmill walking in patients with
IC compared with their healthy counterparts (22, 23, 27).
Restoring the functionality of the NO pathway has long been
considered an attractive therapeutic approach to potentially
improve muscle blood flow and functional capacity in PAD
(61). Phosphodiesterase (PDE) inhibitors have received partic-
ular attention and cilostazol, an inhibitor of PDE type III, is one
of the few drugs approved for the treatment of claudication
(26). Surprisingly, the impact of selective PDE type 5 (PDE5)
inhibitors has not been investigated in this population. Silde-
nafil is a potent PDE5 inhibitor that acts by amplifying NO
effects via an elevation in the available pool of cyclic guanos-
ine monophosphate (cGMP) (53). This drug has been success-
fully used to treat a number of conditions, including erectile
dysfunction, pulmonary hypertension, and congestive heart
failure (CHF) (18, 42). Emerging evidence also indicates that
sildenafil may be effective in lowering blood pressure (BP) in
patients with essential hypertension (35, 36). Recently, our
group has shown that a single oral dose of sildenafil markedly
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reduced skeletal muscle microvascular deoxygenation and in-
creased exercise tolerance by 20% in CHF patients (51).
Using a similar approach, we designed the present study to test
the hypothesis that sildenafil would lower BP and reduce
skeletal muscle deoxygenation during exercise in patients with
IC. We also anticipated that the reduction in muscle deoxy-
genation would translate into an increased walking tolerance in
these individuals.
METHODS
Subjects
Twelve men with a history of IC and an ankle-brachial index (ABI)
lower than 0.9 in at least one leg were recruited from the Claudi-
cation Outpatient Clinic at the Sao Paulo Hospital, a university-
based teaching hospital. Exclusion criteria were 1) diabetes; 2) use
of cilostazol, pentoxifylline, nitrates, and metformin; 3) inability to
walk on the treadmill, and 4) presence of exercise-limiting comor-
bidity (e.g., angina, dyspnea, etc.). All of the patients had signif-
icant aortoiliac or femoropopliteal disease, as confirmed by duplex
ultrasonography scanning. Written informed consent was obtained
from all study participants, and the protocol was approved by the
Institutional Review Board (CAAE no. 14586313.9.0000.5505).
Protocol
In the first visit to the laboratory, the patients underwent a physical
examination and were familiarized with the study protocol. After
recording the anthropometric characteristics, the participants rested
for 15 min in the supine position and the systolic pressures in the arms
and legs were measured for the calculation of the ABI, as described
below. Patients then performed a progressive, symptom-limited exer-
cise test on the treadmill. Individuals that were not familiar with the
treadmill test were required to complete at least two practice sessions.
These patients were only allowed to commence the experimental
protocol when the difference in maximal walking time between two
consecutive tests was less than 20%. Next, in a randomized, crossover
design, the patients were asked to report to the laboratory twice for the
experimental sessions, at least 72 h apart. Subjects took their usual
medication and were instructed to refrain from smoking for at least 4
h prior to the experiments. Upon arrival to the laboratory, the patients
rested in the supine position for 15 min, after which systolic pressure
measurements were taken. The patients then received two consecutive
doses of 50 mg of sildenafil (Viagra, Pfizer) or matching placebo with
a 30-min interval between each dose. Both patients and investigators
were blinded to the assigned treatment. Systolic pressure measure-
ments were repeated 30 min after the final dose following a period of
15 min of resting in the supine position. The patients were then
instrumented and completed a symptom-limited exercise test on the
treadmill as described below. The test began 90 min after ingestion
of the first sildenafil/placebo capsule.
Measurements
ABI. Systolic pressures were measured in duplicate with a hand-
held Doppler system (Micromed, Brasilia, Brazil) in the right and left
brachial and in the dorsalis pedis and posterior tibial arteries. The
ABIs were calculated by dividing the higher ankle pressure (obtained
from the dorsalis pedis or posterior tibial arteries) by the higher of the
two brachial artery pressures.
Treadmill Exercise Test
Patients performed a graded, symptom-limited exercise test on a
treadmill (Super ATL, Inbrasport, Brazil) following the Gardner
protocol (treadmill speed of 2 mph, 0% grade with increments of 2%
every 2 min). During the test, patients were asked to inform us when
the leg symptoms first appeared, which was defined as the pain-free
walking time, and were encouraged to walk until voluntary exhaus-
tion, defined as maximal walking time. Verbal encouragement was
given by the same investigator on all exercise tests. During the
practice sessions, the intraclass correlation coefficients were R 0.79
for the pain-free walking time and R  0.89 for the maximal walking
time. When the patients indicated that they could no longer continue
walking, the treadmill was turned off, and the subjects recovered
standing on the treadmill for 10 min. Gas exchange and ventilatory
variables were measured breath-by-breath during exercise and recov-
ery using a computer-based system (Caro Systems Medical Graphics,
Saint Paul, MN), as described previously (51). The following vari-
ables were determined: pulmonary oxygen uptake (V˙ O2, ml/min),
carbon dioxide output (V˙ CO2, ml/min), respiratory exchange ratio
(RER), minute ventilation (V˙ E, l/min), and ventilatory equivalents for
O2 and CO2 (V˙ E/V˙ O2 and V˙ E/V˙ O2). Heart rate (HR) was determined
by using the R-R interval from a 12-lead electrocardiogram. BP was
measured prior to exercise onset and every 2 min during the test and
during the recovery period by the conventional auscultatory method.
Skeletal Muscle Oxygenation
The microvascular oxygenation status of the medial gastrocnemius
muscle of the most symptomatic leg was monitored using a commer-
cially available NIRS system (NIRO 300; Hamamatsu Photonics,
Hamamatsu City, Japan), as described previously (51). Initially, the
skin in the medial portion of the calf was shaved and cleaned, and the
anatomical location for the optode placement was determined while
the patient was standing on tiptoe. The optode holder was secured to
the skin with adhesive tape and covered with aluminum foil. An
elastic bandage was then wrapped around the entire calf. To ensure
that the probe was positioned in the same location during both
experimental trials, pen marks were made around the probe holder.
The variables assessed by the NIRS system are the concentration of
oxygenated [oxy-HbMb] and deoxygenated [deoxy-HbMb] he-
moglobin  myoglobin, as well as total Hb. As described in detail by
our group (50, 51) and others (14, 17), [deoxy-HbMb] was selected
as the preferred indicator of muscle oxygenation during exercise, as
this signal is relatively insensitive to blood volume changes and is
interpreted, therefore, as a proxy for muscle fractional oxygen extrac-
tion (14, 17). The responses of [deoxy-HbMb] reported herein are
expressed as relative changes from the baseline value.
Data Analysis
Breath-by-breath gas exchange and ventilation responses were
visually inspected, and breaths outside four SDs of the local mean
were deleted. The responses were time-aligned at exercise onset,
interpolated second by second, and averaged into 5-s bins. Gas
exchange and NIRS variables were studied at baseline, defined as the
last 20 s preceding exercise onset, during the last 20 s of stages 1–3
of the exercise test, and at peak (isotime) exercise. Peak (isotime) was
defined as the last 20 s of the test with the shortest duration. Average
values for both NIRS and gas exchange variables were also calculated
every 2 min (last 20 s) during 10 min of recovery. The area under the
curve for the entire recovery period was calculated for [Deoxy-
HbMb].
Statistical Analysis
Data are presented as means  SE. Sample size was estimated on
the basis of a recent study by our group that demonstrated that acute
oral sildenafil improved exercise tolerance by 21% in patients with
CHF (51). Gas exchange, BP, and NIRS variables during exercise and
recovery were compared between conditions with a two-way repeat-
ed-measures ANOVA followed by Tukey’s post hoc test when ap-
R397SILDENAFIL IN INTERMITTENT CLAUDICATION
AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00183.2014 • www.ajpregu.org
propriate. Walking tolerance and the area under the curve for
[Deoxy-HbMb] were compared between conditions with two-
tailed, paired t-tests. Statistical significance was accepted when P 
0.05.
RESULTS
Patient Characteristics
Anthropometric and clinical characteristics of the partici-
pants are shown on Table 1. Sildenafil was well tolerated, and
none of the patients experienced adverse reactions to the drug.
Resting Systolic Pressure
Supine systolic pressures in the arms and ankles measured
with the hand-held Doppler prior to and 1 h after placebo or
sildenafil ingestion are shown in Fig. 1. Baseline pressures
were similar before placebo or sildenafil. There were signifi-
cant differences in systolic pressures between the placebo and
sildenafil conditions after 1 h in the right arm (P  0.002), left
arm (P  0.01) and right ankle (P  0.002) (Fig. 1). The
calculated ABIs for both legs remained unaltered (P  0.05)
after placebo (right ankle, before: 0.60 0.05 and after: 0.60 0.04;
left ankle, before: 0.65  0.06 and after: 0.66  0.06) or
sildenafil (right ankle, before: 0.57  0.05 and after: 0.59 
0.05 and left ankle, before: 0.64  0.07 and after: 0.67 
0.06).
Blood Pressure Responses to Exercise and Recovery
Systolic (SBP) and diastolic (DPB) blood pressure values
before, during and after the treadmill walking test are shown in
Fig. 2. Baseline DPB but not SBP was significantly lower (P
0.05) after sildenafil ingestion relative to placebo. During the
first three stages of the test, SBP was on average 14 mmHg
lower after sildenafil compared with the placebo condition (P
 0.05), while DPB responses were not different between the
two trials (Fig. 2). There were no differences between the two
conditions for peak SBP and DBP. During the recovery period
from exercise, sildenafil ingestion markedly impacted the BP
responses. SBP and DBP were on average18 and7 mmHg
lower (P  0.05) in the sildenafil trial compared with placebo
during the first 10 min of recovery (Fig. 2).
Ventilatory and Gas Exchange Responses
V˙ O2, V˙ CO2, RER, V˙ E, V˙ E/V˙ O2 and V˙ E/V˙ CO2 values during the
treadmill test and during the recovery period are given in
Tables 2 and 3. Because of technical difficulties, gas exchange
Table 1. Demographic and clinical characteristics of
patients with IC
Characteristic Value
No. 12
Age, yr 64 2
Body weight, kg 67 2
Body mass index, kg/m2 24  1
ABI most affected leg 0.53 0.03
ABI least affected leg 0.71 0.07
Race, % White 83
Current smoker, % 33
Past smoker, % 67
Medication, %
Antiplatelet agents 66
Statins 66
Antihypertensive agents
	-blocker 41
Diuretics 41
Calcium channel blocker 25
ACE inhibitor 75
ANG II receptor antagonist 8
Values are expressed as means  SE or percentages. IC, intermittent
claudication; ABI, ankle-brachial index; ACE, angiotensin-converting en-
zyme.
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Fig. 1. Supine systolic blood pressure (SBP)
measured in the brachial artery in the right
(A) and left (B) arms and in the dorsalis pedis
or posterior tibial arteries in the right (C) and
left (D) ankles before and 1 h after placebo
() or sildenafil (Œ). Data are expressed as
means  SE. *P  0.05 for between-treat-
ment comparisons.
R398 SILDENAFIL IN INTERMITTENT CLAUDICATION
AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00183.2014 • www.ajpregu.org
data from one patient were excluded from the analysis. The
profile of V˙ O2 responses during exercise and recovery are
depicted on Fig. 3. There were no differences between the two
experimental conditions for ventilatory and gas exchange vari-
ables.
Skeletal Muscle Deoxygenation Responses
Figure 4, A and B depicts the profile of [Deoxy-HbMb] of
a representative subject during the treadmill test and during the
recovery period in the sildenafil and placebo trials. Relative
changes in [Deoxy-HbMb] were significantly reduced at the
end of the first (P  0.046) and third (P  0.048) stages of
exercise after sildenafil relative to placebo (Fig. 4C). At peak
exercise (isotime), [Deoxy-HbMb] was 34% lower (P 
0.015) during the sildenafil trial compared with the placebo
condition. During the recovery period, there was a tendency for
lower [Deoxy-HbMb] at the end of 2nd minute after silde-
nafil (placebo: 
24  17 vs. sildenafil: 
5  18, P  0.055)
(Fig. 4D). Calculation of the area under the curve for the entire
recovery period also revealed a trend for lower [Deoxy-
HbMb] in the sildenafil trial compared with the placebo
condition (placebo: 43,028  6,116 vs. sildenafil: 38,878 
5,096 M/cm·s; P  0.08).
Walking Tolerance
Pain-free walking time (placebo: 335  42 vs. sildenafil:
294  35 s) and maximal walking time (placebo: 701  58 vs.
sildenafil: 716  62 s) were not different (P  0.05) in the
placebo and sildenafil trials. Peak V˙ O2 (placebo: 14.9 1.2 vs.
sildenafil: 15.1 1.1 ml·kg
1·min
1; P 0.78) and the HR at
the onset of pain (placebo: 89  4 vs. sildenafil: 87  5 bpm;
P 0.87) and at peak exercise (placebo: 103 5 vs. sildenafil:
105  5 bpm, P  0.43) also did not differ in the two
experimental conditions.
DISCUSSION
This is the first study to investigate the acute effects of the
PDE5 inhibitor sildenafil on resting blood pressure and the
physiological responses to exercise in patients with IC. We
found that oral sildenafil reduced BP at rest, during submaxi-
mal exercise, as well as during the recovery period. The drug
also evoked a marked reduction on NIRS-derived [Deoxy-
HbMb] in the gastrocnemius muscle during exercise, a find-
ing that indicates improved microvascular O2 delivery-to-
utilization matching. Despite these salutary effects, sildenafil
failed to affect the time to onset of pain and overall walking
tolerance in these patients.
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Fig. 2. SBP (A) and diastolic blood pressure (DBP; B) at baseline, during the
first three stages of the exercise test, at peak exercise, and during recovery in
the placebo () and sildenafil (Œ) trials. Data are expressed as means  SE.
*P  0.05 for between-treatment comparisons. Rec, recovery.
Table 2. Ventilatory and gas exchange parameters during the first three stages of the treadmill test and at peak exercise
(isotime)
Baseline Stage 1 Stage 2 Stage 3 Peak (Isotime)
PLAC SILD PLAC SILD PLAC SILD PLAC SILD PLAC SILD
V˙ O2, ml/min 230  16 249 19 609 56 597 53 733 59 683 54 776 57 724 60 971  76 973  83
V˙ O2, ml·min
1·kg
1 3.4  0.1 3.6 0.2 8.9 0.6 8.7 0.5 10.8 0.7 10.2 0.7 11.5 0.7 10.8 0.7 14.6  1.2 14.5  1.1
V˙ CO2, ml/min 189  13 206 17 459 41 453 41 591 55 556 49 664 57 629 57 901  76 925  84
RER 0.8  0.01 0.8 0.04 0.7 0.02 0.7 0.01 0.8 0.02 0.8 0.01 0.8 0.02 0.8 0.02 0.9  0.02 0.9  0.01
V˙ E, l/min 7.9  0.3 8.9 0.7 15.9 1.1 15.6 1.1 19.8 1.8 18.9 1.4 21.9 1.7 21.2 1.6 29.7  2.2 31.1  2.4
V˙ E/V˙ CO2 35.4  1.8 37  2.2 27 1.4 26.8 1.6 27.1 1.3 28.2 1.6 28.4 1.2 29.9 1.7 33.4  1.3 32.9  2.1
V˙ E/V˙ CO2 43.1  2.2 44.9 2.5 35.6 1.4 35.2 1.6 33.8 1 34.6 1.5 33.3 0.9 34.4 1.5 33.4  1.3 34.6  1.8
Data are expressed as means SE. PLAC, placebo; SILD, sildenafil; V˙ O2, pulmonary oxygen uptake; V˙ CO2, carbon dioxide output; RER, respiratory exchange
ratio; V˙ E, minute ventilation; V˙ E/V˙ O2, ventilatory equivalent for O2; V˙ E/V˙ CO2, ventilatory equivalent for CO2.
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Effects of Sildenafil on Blood Pressure
Hypertension is a major risk factor for PAD and an impor-
tant contributor to the increased likelihood of cardiovascular
events in individuals with this condition (49, 54). A particu-
larly clinically relevant feature of PAD is an exaggerated BP
response to exercise that is evident even at relatively mild
workloads (5, 32). This abnormal BP response to walking has
been shown to be an independent predictor of all-cause mor-
tality and adverse cerebrovascular and cardiac events in these
patients (13). In the present study, despite the fact that the vast
majority of the patients were on antihypertensive treatment,
several individuals were hypertensive at rest and showed pro-
nounced changes in BP during the treadmill test (Fig. 2). In this
regard, it is worth highlighting that oral sildenafil produced a
modest reduction in BP at rest, as well as during submaximal
exercise intensities (Fig. 2). The degree of BP reduction ob-
served herein is similar to that reported in a number of studies
in healthy controls, hypertensive individuals, and patients with
cardiac disease following acute sildenafil administration (10,
19, 57). The hypotensive effect of sildenafil was especially
noticeable during recovery from exercise (Fig. 2). This obser-
vation might also be clinically meaningful, as previous studies
have shown that the behavior of BP during recovery from
exercise is an important marker of cardiovascular risk in
hypertensive individuals (64). If the BP-lowering effects of
sildenafil reported here are sustained over time during regular
administration, it is fair to speculate that this drug might be a
useful aid in the pharmacological arsenal designed to prevent
cardiovascular events in this population. Nevertheless, our
sample size is small, and larger trials are warranted to docu-
ment the hemodynamic effects of regular sildenafil in patients
with IC. Finally, it must be emphasized that since the antihy-
pertensive medication was not withheld prior to the experi-
ments in the present study, it is impossible to partition the
exclusive effects of sildenafil on blood pressure in these pa-
tients. Numerous reports indicate that the combination of
sildenafil with other pharmacological agents may yield small
additive decreases in blood pressure (21). Thus, the isolated
acute and chronic effects of sildenafil on BP in patients with IC
remain to be determined.
Effects of Sildenafil on Muscle Oxygenation
NIRS has long been considered a useful tool to discriminate
individuals with and without PAD (11, 27) and to grade the
severity of the disease in affected patients (22, 23). Larger
increases in skeletal muscle deoxygenation during exercise
have been found in patients with IC compared with healthy
counterparts, a finding that has been ascribed largely to the
hemodynamic limitations associated with this condition (11,
22, 27). Of note, few therapeutic strategies to date have been
shown to effectively improve muscle oxygenation during ex-
ercise in patients with IC. For example, Beckitt et al. (6)
recently reported that angioplasty, but not supervised exercise
training, modestly improved gastrocnemius muscle oxygen-
ation during submaximal exercise in claudicants (6). In the
present study, we observed that sildenafil reduced [Deoxy-
HbMb] by40% relative to the placebo condition during the
graded treadmill test (Fig. 4C). This finding is in line with a
recent observation from our group that sildenafil reduced
[Deoxy-HbMb] during high-intensity exercise in patients
with CHF (51). The relative changes in [Deoxy-HbMb]
during exercise have been interpreted by several laboratories as
a reflection of the dynamic balance between local O2 supply
and utilization (14, 17). For a given V˙ O2, it is anticipated that
Table 3. Ventilatory and gas exchange parameters during recovery from exercise
2 min 4 min 6 min 8 min 10 min
PLAC SILD PLAC SILD PLAC SILD PLAC SILD PLAC SILD
V˙ O2, ml/min 428  30 442  27 269  14 296  15 243  17 257  14 224  18 241  13 228  18 239 22
V˙ O2, ml·min
1·kg
1 6.4  0.4 6.5  0.3 4  0.2 4.4  0.1 3.6  0.1 3.8  0.2 3.30  0.2 3.5 0.1 3.4 0.2 3.5 0.3
V˙ CO2, ml/min 514  50 520  45 304  24 327  19 247  18 256  13 206  18 224  12 205  17 210 18
RER 1.1 0.05 1.1  0.04 1.1  0.04 1.1  0.03 1  0.06 1  0.02 0.8  0.05 0.9 0.02 0.9 0.03 0.8 0.02
V˙ E, l/min 19  1.6 19.6  1.9 12.9  0.8 13.6  0.4 10.7  0.7 11.2  0.3 9.2  0.7 10.2  0.3 9.3 0.6 9.6 0.3
V˙ E/V˙ O2 44.6  2.5 44.9  3.1 48.3  2.3 47.3  2.6 45.3  3.1 44.9  2.4 39.9  2.5 43.8 2.7 42 2.3 42.7  3
V˙ E/V˙ CO2 38  1.8 38.7  2.4 43.6  2.1 42.8  2.4 44.4  2 44.7  2.1 43.6  2.8 46.9 2.7 46.8 2.3 48.1 3.1
Data are expressed as means SE. PLAC, placebo; SILD, sildenafil; V˙ O2, pulmonary oxygen uptake; V˙ CO2, carbon dioxide output; RER, respiratory exchange
ratio; V˙ E, minute ventilation; V˙ E/V˙ O2, ventilatory equivalent for O2; V˙ E/V˙ CO2, ventilatory equivalent for CO2.
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Fig. 3. Group mean V˙ O2 responses during the
first three stages of the treadmill test and at peak
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an improvement in muscle oxygen delivery would translate
into a reduced fractional oxygen extraction (i.e., a reduction in
[Deoxy-HbMb]), as shown in the present study. This is not
surprising given that sildenafil is a well-known potent vasodi-
lator that acts by increasing the intracellular pool of cGMP,
which prolongs the signaling action of NO in the vasculature
(53). Overall, this observation strengthens the concept that
enhancing NO functional activity can be a potentially useful
strategy to improve leg hemodynamics in patients with IC.
Along these lines, a recent study documented that acute inges-
tion of beetroot juice, which is associated with increased
circulating levels of bioactive nitrite, also evoked marked
improvements in muscle oxygenation during exercise in clau-
dicants (20). Altogether, these observations provide compel-
ling evidence that dietary and pharmacological (or a combina-
tion of both) manipulation of the NO pathway are promising
therapeutic targets to alleviate skeletal muscle ischemia in
patients with IC (1, 61).
Clinical implications. An unexpected finding of this study
was that despite the significant improvement in muscle oxy-
genation during exercise after sildenafil intake, pain-free and
total walking time did not increase compared with placebo.
These findings underscore the complexity of the genesis of
functional impairment in individuals with IC (2). It is well
established that walking impairment in these patients stem
from a combination of several mechanisms that range from
intrinsic skeletal muscle abnormalities to poor walking econ-
omy (2, 16, 40). In essence, targeting only one of the multiple
mechanisms that underlie the exercise intolerance in these
individuals might be insufficient to promote an acute improve-
ment in performance (8). An alternative explanation is that the
magnitude of the improvement in muscle oxygenation evoked
by sildenafil was insufficient to be translated into a measurable
change in walking tolerance. However, this seems unlikely as
the improvement observed herein is comparable to that
achieved after angioplasty (6), which typically enhances walk-
ing tolerance in patients with IC (6, 62). Lastly, it is worth
highlighting that NIRS measurements were performed in a
single site in the gastrocnemius muscle, and it is unclear
whether the observed local improvement in microvascular O2
delivery-to-utilization matching after sildenafil extends to the
other regions of the muscle, as well as to other muscles in the
leg recruited during walking. Using mathematical simulations,
Sprague and co-workers have shown that a potential caveat of
the administration of vasodilators as a means to restore tissue
oxygenation is that blood flow theoretically increases nonse-
lectively within the microvascular network and, therefore, this
strategy may fail to fully correct potential mismatches between
O2 supply and demand (52). If true for the exercising muscles,
it is conceivable that undersupplied regions would still be
present in the tissue after sildenafil administration, therefore,
precluding a measurable impact on exercise tolerance. This
scenario is nonetheless hypothetical, and future studies with
multisite NIRS measurements that encompass a larger area of
the active muscle mass are required to determine the impact of
sildenafil on the spatial heterogeneity of muscle deoxygenation
during exercise in patients with IC.
The improvement in skeletal muscle oxygenation observed
in the present study can be particularly meaningful when
considering the deleterious impact of ischemia/reperfusion
triggered by exercise in these patients (9). Exercise-induced
muscle ischemia in patients with IC evokes a potent increase in
local and systemic markers of inflammation and oxidative
stress (33, 47, 56), as well as an acute impairment in vascular
reactivity (48). Repeated exposure to cycles of ischemia-
reoxygenation injury during ambulatory activity in these
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patients is thought to contribute, among others, to the
development of skeletal muscle abnormalities, including
fibrosis and mitochondrial dysfunction (39). Conceivably,
the reduction in the magnitude of muscle deoxygenation
during exercise achieved after sildenafil administration can
potentially abrogate the harmful inflammatory response to
exertion in these patients and as a consequence prevent the
maladaptations in skeletal muscle. Interestingly, sildenafil
has a well-established protective effect against ischemia/
reperfusion in the heart (24), and as recently shown by
Armstrong et al. (4), might also reduce ischemic damage in
skeletal muscle following a period of ischemia (4). These
encouraging findings prompt the need for future studies to
determine the impact of sildenafil on the inflammatory
responses to exercise in patients with IC.
Study Limitations
The exercise test started 60 min after the final oral dose of
sildenafil. The rationale behind this choice is based on the
observation that sildenafil exhibits rapid oral absorption, and
peak plasma concentrations are typically achieved 1 h after
administration (34, 59). However, as we have not studied the
pharmacokinetic profile of the dosing regimen employed
herein, it is unclear whether the maximal possible physiolog-
ical inhibition of PDE5 was, indeed, attained in these patients.
Another major limitation of the present study is that we
focused only in the acute responses to sildenafil administration.
Regular, long-term treatment with the drug might evoke a
number of beneficial adaptations that cannot be perceived in a
single-dose study. This notion is supported by findings from
studies with other pharmacological agents, such as the selec-
tive PDE type III inhibitor cilostazol. The clinical benefits of
cilostazol increase progressively during 24 wk of treatment in
patients with IC (12). As pointed out by Brass (8), this finding
suggests that an adaptive process rather that an acute vasodi-
latory action mediate the positive effects of this drug on
walking tolerance in patients with IC. In agreement with this
concept, several recent studies have documented beneficial
adaptations following repeated, long-term administration of
sildenafil. Senthilkumar et al. (44) showed that regular silde-
nafil administration restored blood flow and increased vascular
density in the ischemic skeletal muscle in a preclinical model
of PAD. As PDE5 is also expressed in skeletal muscle cells
(60), it has been proposed that chronic sildenafil treatment
might also trigger beneficial changes in this tissue (37). Per-
cival et al. (38) showed that a 14-wk treatment with sildenafil
reduced respiratory muscle weakness and fibrosis in the mdx
mouse model of Duchenne muscular dystrophy. In humans, a
recent study documented that sildenafil administration for 8
consecutive days nearly doubled skeletal muscle protein syn-
thesis and reduced muscle fatigue in healthy subjects (45). On
the basis of these observations, future studies are needed to
verify the long-term consequences of regular sildenafil admin-
istration in patients with IC. Anecdotal observations have been
reported that regular sildenafil was associated with alleviation
of the leg symptoms in a patient with claudication (55).
Whether similar outcomes will hold true in larger, randomized
controlled trials remains to be determined.
Conclusions
Current pharmacological management of IC is aimed at
reducing the risk of cardiovascular events and alleviating the
leg ischemia induced by exercise. Results from the present
study suggest that sildenafil might fulfill both therapeutic goals
as revealed by the marked reduction in blood pressure and
improved muscle oxygenation during walking in patients with
IC. Nonetheless, the lack of changes in functional performance
after acute administration suggests that long-term, regular
treatment with this drug may be required to evoke meaningful
changes in walking capacity in these individuals.
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